KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Finished Goods (2018 - 2025)

Twist Bioscience (TWST) has disclosed Finished Goods for 8 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 22.43% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, up 22.43% year-over-year, with the annual reading at $5.9 million for FY2025, 26.8% up from the prior year.
  • Finished Goods for Q4 2025 was $5.9 million at Twist Bioscience, up from $5.9 million in the prior quarter.
  • The five-year high for Finished Goods was $9.6 million in Q1 2022, with the low at $1.9 million in Q1 2021.
  • Average Finished Goods over 5 years is $5.7 million, with a median of $5.5 million recorded in 2023.
  • The sharpest move saw Finished Goods surged 693.89% in 2021, then plummeted 48.71% in 2023.
  • Over 5 years, Finished Goods stood at $6.8 million in 2021, then rose by 9.9% to $7.4 million in 2022, then crashed by 36.47% to $4.7 million in 2023, then rose by 2.75% to $4.8 million in 2024, then increased by 22.43% to $5.9 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $5.9 million, $5.9 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.